Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease
Chan Ho Chung,Wonsik Jung,Hyeongseop Keum,Tae Woo Kim,Sangyong Jon
DOI: https://doi.org/10.1021/acsnano.0c01018
IF: 17.1
2020-05-25
ACS Nano
Abstract:Rosmarinic acid (RA), one of the most important polyphenol-based antioxidants, has received growing interest because of its bioactive properties, including anti-inflammatory, anticancer, and antibacterial activities. Despite the high therapeutic potential of RA, its intrinsic properties of poor water solubility and low bioavailability have limited its translation into the clinic. Here, we report on the synthesis and preparation of PEGylated RA-derived nanoparticles (RANPs) and their use as a therapeutic nanomedicine for treatment of inflammatory bowel disease (IBD) in a dextran sulfate sodium (DSS)-induced acute colitis mouse model. PEGylated RA, synthesized <i>via</i> a one-step process from RA and a PEG-containing amine, self-assembled in buffer to form nanoparticles (RANPs) with a diameter of 63.5 ± 4.0 nm. The resulting RANPs showed high colloidal stability in physiological medium up to 2 weeks. RANPs were capable of efficiently scavenging H<sub>2</sub>O<sub>2</sub>, thereby protecting cells from H<sub>2</sub>O<sub>2</sub>-induced damage. Furthermore, the corticosteroid drug, dexamethasone (DEX), could be loaded into RANPs and released in response to a reactive oxygen species stimulus. Intravenously administered RANPs exhibited significantly improved pharmacokinetic parameters compared with those of the parent RA and were preferentially localized to the inflamed colon. Intravenous administration of RANPs in DSS-induced colitis mice substantially mitigated colonic inflammation in a dose-dependent manner compared with the parent RA, as evidenced by significantly reduced disease activity index scores, body weight loss, and colonic inflammatory damage. In addition, RANPs suppressed expression and production of typical pro-inflammatory cytokines in the inflamed colon. Furthermore, DEX-loaded RANPs showed enhanced therapeutic efficacy in the colitis model compared with bare RANPs at the equivalent dose, indicating synergy with a conventional medication. These findings suggest that RANPs deserve further consideration as a potential therapeutic nanomedicine for the treatment of various inflammatory diseases, including IBD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c01018?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c01018</a>.<sup>1</sup>H NMR, MALDI-TOF, UV–vis absorbance, FT-IR data of RA, mPEG<sub>2k</sub>-NH<sub>2</sub> and PEG-RA; schematic illustration of RANP formation; zeta potential, mobility, and conductivity values, particle size and stability data of RANPs; changes in the size of RANPs induced by ROS (H<sub>2</sub>O<sub>2</sub>) stimulation; schematic illustration of formation, HPLC analysis and particle size distribution data of ; therapeutic effects of RANPs at doses of 50 and 100 mg/kg; comparison of therapeutic effects between RA and RANPs; cross-sectioned H&E images of RANP-treated colons; muscle thickness of colon sections and estimated inflammation score in DSS-induced colitis mice; representative photomicrographs of IHC sections of colons for pSTAT3, NF-kB, and neutrophils; a table for assessment of DAI; a table for assessment of histopathological colitis (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c01018/suppl_file/nn0c01018_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology